Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18759850 | 0.90 | ALPL (0.54) | PIK3CAALPLPIK3CDPIK3CBCYP3A4 | |
| SCHEMBL30333601 | 0.90 | ALPL (0.54) | PIK3CAALPLPIK3CDPIK3CBCYP3A4 | |
| SCHEMBL798076 | 0.90 | ALPL (0.47) | PIK3CAALPLPIK3CDPIK3CBBRD4 | |
| SCHEMBL22447743 | 0.88 | ALPL (0.45) | PIK3CAALPLPIK3CDPIK3CBCYP3A4 | |
| SCHEMBL22447563 | 0.85 | PIK3C3 (0.43) | PIK3CAALPLBRD4 | |
| SCHEMBL9953341 | 0.84 | ALPL (0.51) | PIK3CAALPLPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL22447742 | 0.83 | PIK3CA (0.45) | PIK3CAALPLPIK3CDBRD4 | |
| SCHEMBL22508715 | 0.81 | ALPL (0.39) | PIK3CAALPLBRD4 | |
| SCHEMBL110313 | 0.81 | ALPL (0.55) | PIK3CAALPLPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL29556110 | 0.81 | ALPL (0.55) | PIK3CAALPLPIK3CDPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317660-A1 | Quinazolinone Compound and Application Thereof | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-3712143-A1 | QUINAZOLINONE COMPOUND AND APPLICATION THEREOF | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317660-A1 | Quinazolinone Compound and Application Thereof | PIK3CD, PIK3CA, PIK3R5 | PIK3CA 2/4885ALPL 2879/4885PIK3CD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.